Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
Judd Klingerman's selected project will take him to Madrid, Spain, for six weeks this summer.
The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...